amifostine anhydrous has been researched along with Cancer of Rectum in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria." | 2.75 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010) |
| "A total of 92 patients with colorectal cancer or gastric cancer were enrolled, and randomly assigned to receive amifostine (500 mg/m2)(amifostine group, 46 patients) or glutamine (1500 mg/m2) (control group, 46 patients) just before oxaliplatin infusion." | 2.73 | [Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors]. ( Fan, QX; Lu, P; Wang, LX; Wang, RL; Wang, X; Zong, H, 2008) |
| "Peripheral lymphocytes of twelve rectal cancer patients who had undergone postoperative radiochemotherapy 2-3 years ago were investigated for residual chromosomal damage using 24-color fluorescence in situ hybridization (24-color FISH)." | 2.71 | Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. ( Claussen, U; Dreidax, M; Dunst, J; Kuechler, A; Liehr, T; Pigorsch, SU; Wendt, TG, 2003) |
| " 5-FU chemotherapy was administered as 120-hours continuous infusion in the first and fifth radiation week via a central venous catheter in a daily dosage of 1,000 mg/m2." | 2.69 | Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. ( Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, P | 1 |
| Fan, QX | 1 |
| Wang, LX | 1 |
| Wang, X | 1 |
| Zong, H | 1 |
| Wang, RL | 1 |
| Katsanos, KH | 1 |
| Briasoulis, E | 1 |
| Tsekeris, P | 1 |
| Batistatou, A | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Capizzello, A | 1 |
| Panelos, I | 1 |
| Karavasilis, V | 1 |
| Christodoulou, D | 1 |
| Tsianos, EV | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Tsoutsou, P | 1 |
| Lyratzopoulos, N | 1 |
| Pitiakoudis, M | 1 |
| Kouklakis, G | 1 |
| Chloropoulou, PA | 1 |
| Manolas, K | 1 |
| Sivridis, E | 1 |
| Myerson, R | 2 |
| Zobeiri, I | 1 |
| Birnbaum, E | 1 |
| Dietz, D | 1 |
| Fleshman, J | 1 |
| Kodner, I | 1 |
| Picus, J | 1 |
| Ratkin, G | 1 |
| Kuechler, A | 1 |
| Dreidax, M | 1 |
| Pigorsch, SU | 1 |
| Liehr, T | 1 |
| Claussen, U | 1 |
| Wendt, TG | 1 |
| Dunst, J | 2 |
| Mazeron, JJ | 1 |
| Capizzi, RL | 1 |
| Semlin, S | 1 |
| Pigorsch, S | 1 |
| Müller, AC | 1 |
| Reese, T | 1 |
| Kligerman, MM | 2 |
| Liu, T | 2 |
| Liu, Y | 2 |
| Scheffler, B | 1 |
| He, S | 2 |
| Zhang, Z | 2 |
| Rivoire, M | 1 |
1 review available for amifostine anhydrous and Cancer of Rectum
| Article | Year |
|---|---|
Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Female; Humans; Male; Ne | 1994 |
8 trials available for amifostine anhydrous and Cancer of Rectum
| Article | Year |
|---|---|
[Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors].
Topics: Amifostine; Antineoplastic Agents; Colonic Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasm | 2008 |
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U | 2010 |
Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibod | 2011 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Aberrations; C | 2003 |
Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Topics: Amifostine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Fluoro | 2000 |
Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Humans; Middle Aged; | 1992 |
Use of radiation with or without WR-2721 in advanced rectal cancer.
Topics: Adult; Aged; Amifostine; Female; Humans; Male; Middle Aged; Preoperative Care; Radiation Injuries; R | 1992 |
4 other studies available for amifostine anhydrous and Cancer of Rectum
| Article | Year |
|---|---|
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
[Cancers of the colon and the rectum: news in 1992].
Topics: Amifostine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusio | 1992 |